10-Q: Sotera Health Q1 2026: Revenue Up, Net Income Positive

Sotera Health Company reported a 10% increase in net revenues for the first quarter of 2026, driven by growth across its segments, and a return to net income after a loss in the prior year period.

Summary

• Sotera Health Company's net revenues for the first quarter of 2026 reached $280.0 million, a 10.0% increase compared to $254.5 million in the same period of 2025.
• Service revenues grew by 7.9% to $241.6 million, while product revenues saw a significant increase of 25.7% to $38.4 million.
• The company reported a net income of $26.6 million for the quarter, a substantial improvement from a net loss of $13.3 million in Q1 2025.
• Adjusted Net Income increased by 34.1% to $52.4 million, and Adjusted EBITDA rose by 10.5% to $134.7 million.
• Capital expenditures increased significantly to $46.2 million in Q1 2026 from $19.9 million in Q1 2025.
• Cash provided by operating activities decreased to $29.4 million from $55.5 million, largely due to a $34.0 million payment for the Illinois EO litigation settlement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and a return to profitability, although the significant increase in capital expenditures and the ongoing impact of litigation costs warrant close monitoring.

Positives

• Total net revenues increased by 10.0% to $280.0 million in Q1 2026.
• Service revenues grew by 7.9% to $241.6 million, driven by favorable pricing and volume/mix in Sterigenics and Nelson Labs, and currency tailwinds.
• Product revenues surged by 25.7% to $38.4 million, primarily due to favorable Co-60 harvest timing at Nordion and pricing benefits.
• The company returned to profitability with a net income of $26.6 million in Q1 2026, compared to a net loss of $13.3 million in Q1 2025.
• Adjusted Net Income increased by 34.1% to $52.4 million, indicating strong operational performance.
• Adjusted EBITDA grew by 10.5% to $134.7 million, demonstrating improved operational profitability.
• Sterigenics segment income increased by 9.6% to $96.4 million.
• Nordion segment income saw a substantial increase of 36.1% to $23.7 million, driven by favorable Co-60 harvest timing and pricing.
• The company has $591.7 million in availability under its Revolving Credit Facility.

Negatives

• Total cost of revenues increased by 11.7% to $133.0 million, outpacing revenue growth.
• Cost of service revenues increased by 10.4% due to higher employee compensation, depreciation, and direct material costs.
• Cost of product revenues increased by 23.4%, primarily due to higher volumes of Co-60 shipments and associated transportation costs.
• Nelson Labs segment net revenues decreased by 0.7% to $51.9 million due to an unfavorable change in volume/mix.
• Nelson Labs segment income decreased by 11.5% to $14.5 million, impacted by lower volume/mix.
• Cash provided by operating activities decreased by $26.1 million to $29.4 million, primarily due to the $34.0 million Illinois EO litigation settlement payment.
• Capital expenditures more than doubled to $46.2 million in Q1 2026 from $19.9 million in Q1 2025.
• Amortization of intangible assets decreased significantly by 80.2% due to certain assets being fully amortized, which is a one-time benefit.

Risks

• Disruption in the availability or price of ethylene oxide (EO), Cobalt-60 (Co-60), or other direct materials.
• Fluctuations in foreign currency exchange rates.
• Evolving environmental, health, and safety regulations.
• Health and safety risks associated with hazardous materials like EO and Co-60.
• The impact and outcome of current and future legal proceedings, including litigation related to EO emissions.
• Allegations of failure to properly perform services and potential product liability claims.
• Compliance with extensive regulatory requirements and potential delays in obtaining clearances or approvals.
• Adverse changes in industry trends and competition.
• Market conditions, including inflationary trends and tariffs, impacting long-term supply contracts.
• Business continuity hazards such as supply chain disruptions and government shutdowns.
• Risks of international operations, including economic and political instability.
• Ability to increase capacity, build new facilities, and renew leases.
• Ability to attract and retain qualified employees.
• Cybersecurity incidents and data disclosures.
• Risks associated with the introduction of artificial intelligence (AI) technology.
• Inability to pursue strategic transactions or integrate acquisitions.
• Maintaining effective internal control over financial reporting.
• Reliance on intellectual property rights and risk of infringement claims.
• Compliance with data privacy and security laws.
• Potential impairment charges on goodwill and other intangible assets.
• Effects of unionization efforts and labor regulations.
• Adverse changes to tax positions.
• Significant degree of leverage and its potential impact on financial flexibility.
• Influence of investment funds affiliated with Warburg Pincus and GTCR.

Future Outlook

The company expects that cash on hand, operating cash flows, and amounts available under its credit facilities will provide sufficient working capital for operations, liquidity requirements, debt service, capital expenditures, and litigation costs for at least the next twelve months and the foreseeable future. Primary long-term liquidity needs include servicing debt, capital expenditures, and funding acquisitions. Excess cash from operations is expected to be allocated to capital expenditures, potential acquisitions, or general corporate purposes.

Management Comments

• "We are driven by our mission: Safeguarding Global Health."
• "Our services are an essential aspect of our customers manufacturing processes and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients."
• "The combination of Sterigenics, our terminal sterilization business, and Nordion, our Co-60 supply business, makes us the only vertically integrated global gamma sterilization provider in the sterilization industry."
• "Management believes Adjusted Net Income and Adjusted EBITDA are useful because they allow management to more effectively evaluate our operating performance and compare the results of our operations from period to period without the impact of certain non-cash items and non-routine items that we do not expect to continue at the same level in the future and other items that are not core to our operations."

Industry Context

StockSavvy.ai notes that Sotera Health's Q1 2026 results reflect continued demand for sterilization and lab testing services within the healthcare industry, a sector benefiting from an aging global population and increasing healthcare spending. The company's vertical integration in gamma sterilization and its diverse service offerings position it to capitalize on these trends, though it faces challenges common to the industry, such as regulatory scrutiny and litigation risks related to its sterilization processes.

Comparison to Industry Standards

• Sotera Health's revenue growth of 10.0% in Q1 2026 is robust compared to the broader healthcare services sector, which typically sees more moderate single-digit growth.
• The company's Adjusted EBITDA margin of approximately 48.1% (calculated as $134.7M / $280.0M) is exceptionally high, indicating strong pricing power and operational efficiency, likely exceeding industry benchmarks for specialized sterilization and testing services.
• Competitors in sterilization services, such as STERIS (though with a broader portfolio) and smaller regional players, may not offer the same level of vertical integration as Sotera Health's Sterigenics and Nordion combination.
• In the lab testing segment, Nelson Labs competes with numerous specialized contract research organizations (CROs) and larger testing conglomerates, where margins can vary significantly based on service specialization and client base.

Legal Proceedings

• Ethylene Oxide Tort Litigation: Lawsuits alleging personal injury or wrongful death from EO exposure are ongoing in California (approx. 140 claims), Georgia (approx. 470 claims), Illinois (approx. 10 cases), and New Mexico (NMAG lawsuit). Initial trials in California are scheduled for January and April 2027. Georgia cases have seen complex rulings on general and specific causation, with appeals ongoing. The Illinois cases are in various stages of litigation. The New Mexico case is set for trial in July 2026.
• Insurance Coverage for Environmental Liabilities: Sterigenics is involved in litigation regarding insurance coverage for EO tort lawsuits. Recent rulings have favored insurers, leading Sterigenics to withdraw claims under certain policies.
• Sotera Health Company Securities Litigation: A stockholder class action was dismissed with prejudice, and a subsequent stockholder derivative lawsuit was voluntarily dismissed following the affirmation of the class action dismissal.

Stakeholder Impact

• Shareholders: Positive impact from return to net income and revenue growth, but potential concerns remain regarding litigation costs and increased capital expenditures.
• Employees: Continued employment and potential for share-based compensation, but subject to company performance and operational risks.
• Customers: Continued provision of essential sterilization and testing services, with potential benefits from company's vertical integration and expertise.
• Creditors: Company's leverage and debt service obligations remain a factor, though liquidity appears sufficient for the near term.

Next Steps

• Continue to monitor the outcomes of ongoing legal proceedings, particularly the Ethylene Oxide tort litigation in California, Georgia, Illinois, and New Mexico.
• Manage and execute capital expenditure plans, which have significantly increased in Q1 2026.
• Focus on operational efficiency and cost management across all segments, especially in Nelson Labs where revenue and income saw a slight decline.
• Continue to leverage vertical integration in gamma sterilization through Sterigenics and Nordion.
• Monitor foreign currency exchange rate fluctuations and their impact on revenues and costs.

Key Dates

Recommendation

The company shows strong revenue growth and a return to profitability, which is positive. However, the significant increase in capital expenditures, ongoing substantial legal proceedings related to EO litigation, and the decrease in performance at Nelson Labs introduce considerable uncertainty. While the core business appears healthy, the resolution of litigation and the successful deployment of increased capital expenditures are key factors that need to be monitored before a more aggressive stance can be taken.

Keywords

Sotera Health, 10-Q, Quarterly Report, Sterilization Services, Ethylene Oxide, Cobalt-60, Nelson Labs, Nordion, Healthcare Industry, Medical Devices, Pharmaceuticals, Financial Results, Litigation